4RVM

CHK1 kinase domain with diazacarbazole compound 19


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.86 Å
  • R-Value Free: 0.242 
  • R-Value Work: 0.201 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Mitigation of Acetylcholine Esterase Activity in the 1,7-Diazacarbazole Series of Inhibitors of Checkpoint Kinase 1.

Gazzard, L.Williams, K.Chen, H.Axford, L.Blackwood, E.Burton, B.Chapman, K.Crackett, P.Drobnick, J.Ellwood, C.Epler, J.Flagella, M.Gancia, E.Gill, M.Goodacre, S.Halladay, J.Hewitt, J.Hunt, H.Kintz, S.Lyssikatos, J.Macleod, C.Major, S.Medard, G.Narukulla, R.Ramiscal, J.Schmidt, S.Seward, E.Wiesmann, C.Wu, P.Yee, S.Yen, I.Malek, S.

(2015) J.Med.Chem. 58: 5053-5074

  • DOI: 10.1021/acs.jmedchem.5b00464
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Checkpoint kinase 1 (ChK1) plays a key role in the DNA damage response, facilitating cell-cycle arrest to provide sufficient time for lesion repair. This leads to the hypothesis that inhibition of ChK1 might enhance the effectiveness of DNA-damaging ...

    Checkpoint kinase 1 (ChK1) plays a key role in the DNA damage response, facilitating cell-cycle arrest to provide sufficient time for lesion repair. This leads to the hypothesis that inhibition of ChK1 might enhance the effectiveness of DNA-damaging therapies in the treatment of cancer. Lead compound 1 (GNE-783), the prototype of the 1,7-diazacarbazole class of ChK1 inhibitors, was found to be a highly potent inhibitor of acetylcholine esterase (AChE) and unsuitable for development. A campaign of analogue synthesis established SAR delineating ChK1 and AChE activities and allowing identification of new leads with improved profiles. In silico docking using a model of AChE permitted rationalization of the observed SAR. Compounds 19 (GNE-900) and 30 (GNE-145) were identified as selective, orally bioavailable ChK1 inhibitors offering excellent in vitro potency with significantly reduced AChE activity. In combination with gemcitabine, these compounds demonstrate an in vivo pharmacodynamic effect and are efficacious in a mouse p53 mutant xenograft model.


    Organizational Affiliation

    ∇Argenta, A Charles River Company, 8-9 Spire Green Centre, Harlow, Essex CM19 5TR, United Kingdom.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Serine/threonine-protein kinase Chk1
A
298Homo sapiensMutation(s): 0 
Gene Names: CHEK1 (CHK1)
EC: 2.7.11.1
Find proteins for O14757 (Homo sapiens)
Go to Gene View: CHEK1
Go to UniProtKB:  O14757
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
3X7
Query on 3X7

Download SDF File 
Download CCD File 
A
3-[4-(piperidin-1-ylmethyl)phenyl]-9H-pyrrolo[2,3-b:5,4-c']dipyridine-6-carbonitrile
C23 H21 N5
PPYHOOZGDDPLKM-UHFFFAOYSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
3X7EC50: 53 nM (98) BINDINGDB
3X7IC50: 1 nM (98) BINDINGDB
3X7IC50: 1 nM BINDINGMOAD
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.86 Å
  • R-Value Free: 0.242 
  • R-Value Work: 0.201 
  • Space Group: P 1 21 1
Unit Cell:
Length (Å)Angle (°)
a = 45.123α = 90.00
b = 65.930β = 94.63
c = 58.117γ = 90.00
Software Package:
Software NamePurpose
AMoREphasing
HKL-2000data reduction
REFMACrefinement
JDirectordata collection
HKL-2000data scaling

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Revision History 

  • Version 1.0: 2015-06-03
    Type: Initial release
  • Version 1.1: 2015-08-26
    Type: Database references
  • Version 1.2: 2017-11-22
    Type: Refinement description